Aelis Farma SA AELIS

BORDEAUX, France, September 24, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2026 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers).

The global cannabis use disorder market is projected to grow significantly from 2025 to 2035, driven by cannabis legalization, rising awareness, research funding and demand for effective addiction treatments. Investigational therapies include cannabinoid receptor modulators and serotonin-based drugs, such as Aelis Farma’s AEF0117 and Anebulo Pharmaceuticals’ ANEB-001. North America is expected to lead, followed by Europe, while Asia-Pacific and other regions offer emerging opportunities. Key bar

BORDEAUX, France, September 15, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor of the endocannabinoid system, today announces its financial results for the first half of 2026 and provides an update on its progress and development outlook.

BORDEAUX, France, July 16, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that the Independent Data Monitoring Committee ("IDMC") has recommended the continuation, without modification, of the ongoing Phase 2b clinical trial evaluating AEF0217 in adults and older adolescents with Down syndrome.

BORDEAUX, France, June 22, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026.

BORDEAUX, France, June 04, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.

As European markets navigate the complexities of geopolitical developments and economic shifts, investors are increasingly attentive to opportunities that may arise from these changes. Penny stocks, while often seen as remnants of past market trends, continue to offer intriguing possibilities for those seeking growth potential in smaller or newer companies. With a focus on financial resilience, this article will explore three penny stocks that stand out for their balance sheet strength and...

The global cannabis use disorder market is rapidly expanding, driven by increased recognition of cannabis use as a public health issue and the ongoing development of investigational treatments, including cannabinoid receptor antagonists. With no FDA-approved medications specifically for cannabis use disorder, the market is fueled by the rising need for effective therapies, awareness of the disorder's impact, and growing research funding. Challenges like regulatory hurdles and lack of standardize

As the pan-European STOXX Europe 600 Index edges closer to record highs amid optimism about future earnings and economic prospects, investors are keenly observing the high-growth tech sector, which remains a focal point of innovation and potential. In such an environment, identifying promising stocks often involves looking for companies with robust growth trajectories and adaptability to evolving technological trends, making them standouts in a dynamic market landscape.

As European markets close out a holiday-shortened week, the pan-European STOXX Europe 600 Index edged slightly higher, buoyed by positive sentiment around future earnings and economic prospects. In this environment, identifying promising tech stocks involves looking for companies that can leverage emerging technologies and navigate market challenges effectively to sustain growth.

The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% due to relief from the reopening of the U.S. federal government, although enthusiasm for artificial intelligence investments has cooled. In this context, identifying promising investment opportunities requires a focus on stocks that combine potential growth with strong fundamentals. Penny stocks may be an outdated term, but they continue to represent intriguing possibilities in smaller or...